ReviewViruses2020
Dysregulated Interferon Response Underlying Severe COVID-19.
Review in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2021Pooled it
- Type I Interferons in SARS-CoV-2 Cutaneous Infection: Is There a Role in Antiviral Defense?International journal of molecular sciences · 2025Article
- Individuals with latent tuberculosis in a high TB endemic country show mild COVID-19.PloS one · 2025Article
- What goes up must come down: dynamics of type 1 interferon signaling across the lifespan.Frontiers in immunology · 2025Review
- Correlates of disease severity in bluetongue as a model of acute arbovirus infection.PLoS pathogens · 2024Article
- STING agonists as promising vaccine adjuvants to boost immunogenicity against SARS-related coronavirus derived infection: possible role of autophagy.Cell communication and signaling : CCS · 2024Review
- Antiviral Therapy of COVID-19.International journal of molecular sciences · 2023Review
- Evaluation of the interaction between tumor growth factor-β and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90 years.BMC infectious diseases · 2023Article
- Therapeutic Effectiveness of Interferon-α2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience.International journal of molecular sciences · 2023Article
- Severe COVID-19European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Decrypting the cellular and molecular intricacies associated with COVID-19-induced chronic pain.Metabolic brain disease · 2022Review
- Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients.Cells · 2022Article
- Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.Biomedicines · 2022Review
- Phase separation in immune regulation and immune-related diseases.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Plasma Torquetenovirus (TTV) microRNAs and severity of COVID-19.Virology journal · 2022Article
- Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19.Nutrients · 2022Review
- Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review.Cytokine & growth factor reviews · 2022Review
- Lack of efficacy of mono-mode of action therapeutics in COVID-19 therapy - How the lack of predictive power of preclinical cell and animal studies leads developments astray.Chemical biology & drug design · 2022Article
- The role of type I interferon in the treatment of COVID-19.Journal of medical virology · 2022Review
- An Evolutionary Insight Into the Heterogeneous Severity Pattern of the SARS-CoV-2 Infection.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Innate immune interferons (IFNs), including type I and III IFNs, constitute critical antiviral mechanisms. Recent studies reveal that IFN dysregulation is key to determine COVID-19 pathogenesis. Effective IFN stimulation or prophylactic administration of IFNs at the early stage prior to severe COVID-19 may elicit an autonomous antiviral state, restrict the virus infection, and prevent COVID-19 progression. Inborn genetic flaws and autoreactive antibodies that block IFN response have been significantly associated with about 14% of patients with life-threatening COVID-19 pneumonia. In most severe COVID-19 patients without genetic errors in IFN-relevant gene loci, IFN dysregulation is progressively worsened and associated with the situation of pro-inflammation and immunopathy, which is prone to autoimmunity. In addition, the high correlation of severe COVID-19 with seniority, males, and individuals with pre-existing comorbidities will be plausibly explained by the coincidence of IFN aberrance in these situations. Collectively, current studies call for a better understanding of the IFN response regarding the spatiotemporal determination and subtype-specificity against SARS-CoV-2 infections, which are warranted to devise IFN-related prophylactics and therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.